SCHEMBL5880276

SCHEMBL5880276

O=C(Cc1c(F)cccc1C(F)(F)F)N/N=C/c1ccccc1OS(=O)(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.45
MAPT P10636 5/20 0.45
KMT2A Q03164 5/20 0.45
HTT P42858 3/20 0.45
MEN1 O00255 3/20 0.45
PTGS2 P35354 2/20 0.42
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MAPK1 P28482 1/20 0.39
ANO1 Q5XXA6 1/20 0.39
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5880279 1.00 LMNA (0.45) LMNAMAPTKMT2AHTTMEN1
SCHEMBL5880162 0.95 KMT2A (0.48) LMNAMAPTKMT2AHTTMEN1
SCHEMBL5880167 0.95 KMT2A (0.48) LMNAMAPTKMT2AHTTMEN1
SCHEMBL5879735 0.89 KMT2A (0.46) LMNAMAPTKMT2AHTTMEN1
SCHEMBL5879738 0.89 KMT2A (0.46) LMNAMAPTKMT2AHTTMEN1
SCHEMBL5880172 0.88 KMT2A (0.48) LMNAMAPTKMT2AHTTMEN1
SCHEMBL5880178 0.88 KMT2A (0.48) LMNAMAPTKMT2AHTTMEN1
SCHEMBL5880121 0.87 KMT2A (0.48) LMNAMAPTKMT2AHTTMEN1
SCHEMBL5880126 0.87 KMT2A (0.48) LMNAMAPTKMT2AHTTMEN1
SCHEMBL5879723 0.85 LMNA (0.44) LMNAMAPTKMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 LMNA 4281/4885MAPT 4629/4885KMT2A 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.